Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Meyer

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Pharmacokinetics|January 1, 2017
Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic PatientsChristian Radke, Dagmar Horn, Christian Lanckohr, et al.
Plos One|July 15, 2016
Correction: Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval ZebrafishMichaela Meyer, Sameer C Dhamne, Christopher M LaCoursiere, et al.
Clinical Pharmacokinetics|September 6, 2023
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling ApproachesHauke Ruehs, Alexander Solms, Matthias Frei, et al.
Journal of Breath Research|April 23, 2011
Chronic intestinal Mycobacteria infection: discrimination via VOC analysis in exhaled breath and headspace of feces using differential ion mobility spectrometryRoman Purkhart, Heike Köhler, Elisabeth Liebler-Tenorio, et al.
Brain Research|October 20, 2006
Epileptogenic drugs in a model nervous system: electrophysiological effects and incorporation into a phospholipid layerUlrich Altrup, Marc Häder, José Luis Hernández Cáceres, et al.
Clinical Pharmacokinetics|June 29, 2016
Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsJan-Frederik Schlender, Michaela Meyer, Kirstin Thelen, et al.
Clinical Pharmacokinetics|June 25, 2024
Clinical Pharmacokinetic and Pharmacodynamic Profile of VericiguatAchim Fritsch, Michaela Meyer, Robert O Blaustein, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
Clinical Pharmacokinetics|June 4, 2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection FractionHauke Ruehs, Dagmar Klein, Matthias Frei, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|January 1, 2017
Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic PatientsChristian Radke, Dagmar Horn, Christian Lanckohr, et al.
Plos One|July 15, 2016
Correction: Microarray Noninvasive Neuronal Seizure Recordings from Intact Larval ZebrafishMichaela Meyer, Sameer C Dhamne, Christopher M LaCoursiere, et al.
Clinical Pharmacokinetics|September 6, 2023
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling ApproachesHauke Ruehs, Alexander Solms, Matthias Frei, et al.
Journal of Breath Research|April 23, 2011
Chronic intestinal Mycobacteria infection: discrimination via VOC analysis in exhaled breath and headspace of feces using differential ion mobility spectrometryRoman Purkhart, Heike Köhler, Elisabeth Liebler-Tenorio, et al.
Brain Research|October 20, 2006
Epileptogenic drugs in a model nervous system: electrophysiological effects and incorporation into a phospholipid layerUlrich Altrup, Marc Häder, José Luis Hernández Cáceres, et al.
Clinical Pharmacokinetics|June 29, 2016
Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsJan-Frederik Schlender, Michaela Meyer, Kirstin Thelen, et al.
Clinical Pharmacokinetics|June 25, 2024
Clinical Pharmacokinetic and Pharmacodynamic Profile of VericiguatAchim Fritsch, Michaela Meyer, Robert O Blaustein, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
Clinical Pharmacokinetics|June 4, 2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection FractionHauke Ruehs, Dagmar Klein, Matthias Frei, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Pageof 4